An industry for healthy lives

Vaccines Europe represents all the major vaccine companies operating in Europe which undertake 79% of their global production and more than 50% of their global research projects in the region.

News & press releases

Launch of Innovative Medicines Initiative Programme to Help Respond to Ebola Crisis

2014 11 06 Written by Vaccines Europe

Vaccines Europe is pleased to announce today the launch of Ebola+, the Innovative Medicines Initiative (IMI2) Programme Call to Help Responding to the Ebola Virus Disease (EVD) Crisis. This EUR 280 Million call is expected to bring together pharmaceutical and vaccine companies and researchers working in the space of Ebola and haemorragic fevers prevention and treatment leveraging the already on-going investments to address the current outbreak in West Africa. Read more…

Ongoing efforts to develop a vaccine against Ebola

2014 10 06 Written by Vaccines Europe

Vaccine companies are actively working on the development of effective prophylactic vaccines capable of preventing Ebola Virus Disease (EVD) and halting the ongoing outbreak in West Africa. This is the first outbreak of this kind and it is rapidly spreading across countries in the region, making it unprecedented in size and geographical distribution. So far, the World Health Organisation (WHO) reports 7178 cases, including 3338 deaths. Read more…

Prevent the Preventable: Vaccines Europe Calls for a Coherent Vaccination Strategy in Europe

2014 06 05 Written by Vaccines Europe

(5 June – Lyon, FRANCE): Vaccines Europe today launched a campaign calling for a coherent vaccination strategy in Europe, with a clearer and more comprehensive agenda to “prevent the preventable”.

The campaign’s roadmap “PREVENTION FIRST: Vaccination at the heart of public health” proposes some actions to be addressed by EU authorities to develop a vaccination strategy for Europe. This aims to support EU Members States in achieving their immunisation policy objectives. Spending in primary prevention currently represents less than 3% of Member States’ overall healthcare budgets, and there is plenty of scope for further action to strengthen diseases prevention programmes. Read more…

Page 1 of 912345...Last »